Cautionary statement
This website may contain forward-looking statements under the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as anticipates, believes, expects, plans, intends, may, potential, seeks and similar expressions can identify forward-looking statements.
These statements can address clinical development, regulatory interactions, study timelines, data, partnering, intellectual property, financing, commercialization potential and other future events.
Material risks
Factors that may cause actual outcomes to differ include BioVie’s need for substantial capital; the possibility that candidates do not successfully complete preclinical or clinical testing; failure to obtain regulatory approval; study enrollment, conduct or data-integrity issues; adverse safety findings; competition; intellectual-property risk; reliance on third parties; litigation; and market conditions.
Source of record
A fuller discussion appears in BioVie’s filings with the SEC. Do not place undue reliance on forward-looking statements. Except as required by law, BioVie undertakes no obligation to publicly update them.
Development-stage information can change. Investigational candidates are not approved, and safety and efficacy have not been established. Review source documents and current regulatory disclosures.